Recursion Pharmaceuticals (RXRX)
(Delayed Data from NSDQ)
$5.53 USD
-0.27 (-4.66%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $5.49 -0.04 (-0.72%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, Recursion Pharmaceuticals, Inc. has a market cap of $2.36B, which represents its share price of $5.80 multiplied by its outstanding shares number of 406.49M. As a mid-cap company, RXRX's shareholders are generally exposed to less risk than shareholders of small-cap companies but more risk than large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
RXRX 5.53 -0.27(-4.66%)
Will RXRX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for RXRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RXRX
Recursion Pharmaceuticals (RXRX) Reports Q2 Loss, Beats Revenue Estimates
Recursion Pharmaceuticals to Report Q2 Earnings: What's in the Cards?
RXRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Gilead Sciences (GILD) Expected to Beat Earnings Estimates: Should You Buy?
Recursion Pharmaceuticals (RXRX) Registers a Bigger Fall Than the Market: Important Facts to Note
Why Recursion Pharmaceuticals (RXRX) Dipped More Than Broader Market Today
Other News for RXRX
Decoding Recursion Pharmaceuticals Inc (RXRX): A Strategic SWOT Insight
Recursion Pharmaceuticals Q2 2025 Earnings: Revenue Surpasses Estimates at $19. ...
Recursion Sets $100 Million Partnership Goal by 202
Recursion Pharmaceuticals (RXRX) Exceeds Revenue Expectations in Q2
Recursion Pharmaceuticals (RXRX) Reports Mixed Q2 Results with Revenue Beat